4d
Zacks Investment Research on MSNAMGN's Eczema Drug Meets Goal in Two Late-Stage StudiesAmgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
1d
Medpage Today on MSNRapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results